Cordis-Medinol stent deal
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson subsidiary Cordis will be the exclusive global distributor of a family of bare-metal stents developed by Israel-based Medinol, the firms announce May 23. Cordis expects to help Medinol file for approval of the first products outside the United States in the second half of 2007, and stateside in the first half of 2008. Cordis, maker of the Cypher sirolimus-eluting stent, does not currently offer a bare-metal coronary stent. The deal comes as sales of drug-eluting stents have come under pressure due to safety concerns; Johnson & Johnson also recently halted development of its Conor CoStar paclitaxel-eluting stent after the U.S. pivotal trial failed (1"The Gray Sheet" May 14, 2007, p. 9). Medinol has a history of patent litigation against its former partner, Boston Scientific, which paid Medinol $750 million in a 2005 settlement (2"The Gray Sheet" Sept. 26, 2005, p. 11)...
You may also be interested in...
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
Following Win Over Boston Scientific, Medinol Seeks Taxus Liberté Royalties
Medinol says it will pursue royalties from sales of Boston Scientific's Taxus Liberté drug-eluting stent following a Sept. 21 settlement of the firms' long-running patent infringement suit
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.